研究実績  |  RESULTS ACHIEVEMENT

英文論文

    2022
  • Yanagisawa S, Oikawa Y, Takagi S, Horikoshi Y, Satomura A, Imai K, Sakai J, Ishibashi N, Tarumoto N, Iida S, Nakayama H, Haga Y, Maesaki S, Shimada A. HbA1c level may be a risk factor for oxygen therapy requirement in patients with coronavirus disease 2019. J Diabetes Investig. 2022 May;13(5):909-917. 

  • 2022
  • Shimada A, Toda K, Inoue I, Yamada T, Oikawa Y. Combination of anti-CD25 antibody and poly I:C treatment in pregnant NOD mice may be used as “pregnancy-related” type 1 diabetes model. J Diabetes Investig. 2022 (In press). 

  • 2022
  • Satomura A, Oikawa Y, Haisa A, Suzuki S, Nakanishi S, Katsuki T, Shimada A. Clinical significance of insulin peptide-specific interferon-γ-related immune responses in ketosis-prone type 2 diabetes. J Clin Endocrinol Metab. 2022 Apr 19;107(5):e2124-e2132. 

  • 2022
  • Yamaunochi Y, Shinoda Y, Majima M, Lee J, Inoue I, Maruyama Y, Kurabayashi H. Can outpatient rehabilitation be continued during the COVID-19 pandemic? A report from a Japanese regional medical university hospital. Arch Rehabil Res Clin Transl. 2022 (In press).

  • 2022
  • Oikawa Y, Hashimoto K, Hara K, Morimoto J, Namai K, Tanaka A, Tanaka S, Shimada A. Current clinical state of type 1 diabetes in Saitama prefecture. Diabetol Int. 2022 April 4;13(2):436-446. 

  • 2022
  • Takenaka Y, Inoue I, Nakano T, Ikeda M, Kakinuma Y. Prolonged disturbance of proteostasis induces cellular senescence via temporal mitochondrial dysfunction and subsequent mitochondrial accumulation in human fibroblasts. FEBS J. 2022 Mar;289(6):1650-1667.

  • 2022
  • Takao T, Yanagisawa H, Suka M, Yoshida Y, Onishi Y, Tahara T, Kikuchi T, Kushiyama A, Anai M, Takahashi K, Wakabayashi Sugawa S, Yamazaki H, Kawazu S, Iwamoto Y, Noda M, Kasuga M. Synergistic association of the copper/zinc ratio under inflammatory conditions with diabetic kidney disease in patients with type 2 diabetes: The Asahi Diabetes Complications Study. J Diabetes Investig. 2022 Feb;13(2):299-307. 

  • 2022
  • Horii T, Oikawa Y, Kunisada N, Shimada A, Atsuda K. Acute kidney injury in Japanese type 2 diabetes patients receiving sodium-glucose cotransporter 2 inhibitors: A nationwide cohort study. J Diabetes Investig. 2022 Jan;13(1):42-46.

  • 2021
  • Ikegami Y*, Takenaka Y*, Saito D, Shimada A, Inoue I. Anagliptin Monotherapy for Six Months in Patients With Type 2 Diabetes Mellitus and Hyper-Low-Density Lipoprotein Cholesterolemia Reduces Plasma Levels of Fasting Low-Density Lipoprotein Cholesterol and Lathosterol: A Single-Arm Intervention Trial. J Clin Med Res. 2021;13(10-11):502-509. (* These authors contributed equally to this work.)

  • 2021
  • Itoh D, Inoue K, Saito D, Hamaguchi K, Kaneko K, Sumita T, Inukai K, Inoue I, Shimada A. Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-Naïve Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial. Diabetes Ther. 2021 Dec;12(12):3201-3215.

  • 2021
  • Horii T*, Oikawa Y*, Atsuda K, Shimada A. On-label use of sodium-glucose cotransporter 2 inhibitors may increase the risk of diabetic ketoacidosis in patients with type 1 diabetes. J Diabetes Investig. 2021 Sep;12(9):1586-1593. (*: These authors contributed equally to this work.)

  • 2021
  • Nakano T, Aochi H, Masataka H, Takenaka Y, Fujita K, Tamura M, Soma H, Kamezawa H, Koizumi T, Shibuya H, Inomata R, Okuda A, Murakoshi T, Shimada A, Inoue I. Effects of Pparγ1 deletion on late-stage murine embryogenesis and cells that undergo endocycle. Dev Biol. 2021 Oct;478:222-235.

  • 2021
  • Chujo D, Imagawa A, Yasuda K, Abiru N, Awata T, Fukui T, Ikegami H, Kawasaki E, Katsuki T, Kobayashi T, Kozawa J, Nagasawa K, Ohtsu H, Oikawa Y, Osawa H, Shimada A, Shimoda M, Takahashi K, Tsuchiya K, Tsujimoto T, Yasuda H, Hanafusa T, Kajio H. Japanese Type 1 Diabetes Database Study (TIDE-J): rationale and study design. Diabetol Int. 2021 Sep 6;13(1):288-294. 

  • 2021
  • Yasuda S, Inoue I, Shimada A. Neurofibromatosis Type 1 with Concurrent Multiple Endocrine Disorders: Adenomatous Goiter, Primary Hyperparathyroidism, and Acromegaly. Intern Med. 2021;60(15):2451-2459. 

  • 2021
  • Kurokawa Y, Oikawa Y, Shimada A, Yajima K. Dupilumab-related type 1 diabetes in a patient with atopic dermatitis: a case report. Diabetol Int. 2021 Aug 10;13(1):300-303. 

  • 2021
  • Sugawa SW, Yoshida Y, Hikima Y, Sato H, Shimada A, Noda M, Kushiyama A. Characteristics Associated with Early Worsening of Retinopathy in Patients with Type 2 Diabetes Diagnosed with Retinopathy at Their First Visit: A Retrospective Observational Study. J Diabetes Res. 2021 Jul 17;2021:7572326.

  • 2021
  • Kayamori Y, Nakamura M, Kishi K, Miida T, Nishimura K, Okamura T, Hirayama S, Ohmura H, Yoshida H, Ai M, Tanaka A, Sumino H, Murakami M, Inoue I, Teramoto T, Yokoyama S. Comparison of the Japan Society of Clinical Chemistry reference method and CDC methodfor HDL and LDL cholesterol measurements using fresh sera. Pract Lab Med. 2021 May;25:e00228. 

  • 2021
  • Yamada Y, Sugi K, Gatate Y, Senbonmatsu T, Inoue I, Fukushima K, Iguchi A, Nakajima H, Muramatsu T, Nakano S, Tada H. Premature acute myocardial infarction in a young patient with sitosterolemia. CJC Open. 2021 May 4;3(8):1085-1088.

  • 2021
  • Yasuda S, Inoue K, Iida S, Oikawa Y, Namba A, Isshiki M, Inoue I, Kamei Y, Shimada A, Noda M. Differences in the birthweight of infants born to patients with early- or mid-to-late-detected gestational diabetes mellitus who underwent guideline-based glycemic control. J Diabetes Complications. 2021 Apr;35(4):107850.

  • 2021
  • Abiru N, Shimada A, Nishimura R, Matsuhisa M, Ozaki A, Ikegami H. Glycemic control status, diabetes management patterns, and clinical characteristics of adults with type 1 diabetes in Japan: Study of Adults’ Glycemia in T1DM subanalysis. Diabetol Int. 2021 Apr 25;12(4):460-473.

  • 2021
  • Sasako T, Ueki K, Miyake K, Okazaki Y, Takeuchi Y, Ohashi Y, Noda M, Kadowaki T. Effect of a multifactorial intervention on fracture in patients with type 2 diabetes: sub-analysis of the J-DOIT3 study.  J Clin Endocrinol Metab. 2021 Apr 23;106(5):e2116-e2128. 

  • 2021
  • Kawasaki E, Oikawa Y, Okada A, Kanatsuna N, Kawamura T, Kikuchi T, Terasaki J, Miura J, Ito Y, Hanafusa T. Different Interaction of Onset Age and Duration of Type 1 Diabetes on the Dynamics of Autoantibodies to IA-2 and ZnT8. J Diabetes Investig. 2021 Apr;12(4):510-515.

  • 2021
  • Koizumi T, Kaneda H, Komiyama N, Inoue I, Muramatsu T, Nakajima K. Lipoprotein Profiles before Heparin Administration in Patients with or without Coronary Thrombosis Following Atherosclerosis. Ann Vasc Dis. 2021 Mar 25;14(1):31-38.

  • 2021
  • Satomura A*, Oikawa Y*, Nakanishi S, Takagi S, Mizutani G, Iida S, Nakayama H, Haga Y, Nagata M, Maesaki S, Mimura T, Shimada A. Clinical features resembling subcutaneous insulin resistance observed in a patient with type 2 diabetes and severe COVID-19-associated pneumonia: a case report. Diabetol Int. 2021 Mar 1:1-6. (*: These authors contributed equally to this work.)

  • 2021
  • Ueki K, Sasako T, Okazaki Y, Miyake K, Nangaku M, Ohashi Y, Noda M, Kadowaki T; J-DOIT3 Study Group. Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes.  Kidney Int. 2021 Jan;99(1):256-266. 

  • 2021
  • Ueki K, Tanizawa Y, Nakamura J, Yamada Y, Inagaki N, Watada H, Shimomura I, Nishimura R, Miyoshi H, Abiko A, Katagiri H, Hayashi M, Shimada A, Naruse K, Fujimoto S, Fujiwara M, Shikata K, Okada Y, Araki E, Yamazaki T, Kadowaki T; J-BRAND Registry Group. Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry). BMJ Open Diabetes Res Care. 2021 Jan;9(1):e001787.

  • 2020
  • Horii T, Oikawa Y, Kunisada N, Shimada A, Atsuda K. Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study. BMJ Open Diabetes Res Care. 2020 Nov;8(2):e001856.

  • 2020
  • Ikegami H, Imagawa A, Shimada A. Fulminant type 1 diabetes: nationwide effort to elucidate genetics, etiology, and pathogenesis since 2000. Diabetol Int. 2020 Oct;11(4):342-343.

  • 2020
  • Shimada A, Ikegami H. Twenty years since the discovery of fulminant type 1 diabetes. Diabetol Int. 2020 Oct;11(4):309.

  • 2020
  • Oikawa Y, Shimada A. Possible involvement of autoimmunity in fulminant type 1 diabetes. Diabetol Int. 2020 Oct;11(4):329–335. 

  • 2020
  • Teratani T, Toma-Fukai S, Nakamura Y, Itoh T, Shimizu H, Shiraishi Y, Sugihara N, Higashiyama M, Shimizu T, Inoue I, Takenaka Y, Hokari R, Adachi T, Shimizu T, Miura S, Kanai T. Redox-dependent PPARγ/Tnpo1 complex formation enhances PPARγ nuclear. Free Radic Biol Med. 2020 Aug 20;156:45-56.

ACCESSご案内

埼玉医科大学

埼玉医科大学病院

〒350-0495 埼玉県入間郡毛呂山町毛呂本郷38
TEL: 049-276-1111(代)
FAX: 049-294-9752

お車をご利用される方
鶴ヶ島インターから約10km(約20~30分)
詳しくはこちら

電車・バスをご利用される方
池袋駅より東毛呂駅まで約1時間
東毛呂駅からバス(約5分)もしくは徒歩(約20分)
詳しくはこちら

本フォームは医療従事者専用となっております。ご病状やお薬、検査、予約など診療に関する患者さんからのご相談は、法律上、一切お受けすることができません。ご理解のほどよろしくお願いいたします。